9 months of delamanid, linezolid, levofloxacin, and pyrazinamide versus conventional therapy for treatment of fluoroquinolone-sensitive multidrug-resistant tuberculosis (MDR-END): a multicentre, randomised, open-label phase 2/3 non-inferiority trial in South Korea

Jeongha Mok, Myungsun Lee, Deog Kyeom Kim, Ju Sang Kim, Byung Woo Jhun, Kyung‐Wook Jo, Doosoo Jeon, Taehoon Lee, Ji Yeon Lee, Jae Seuk Park, Seung Heon Lee, Young Ae Kang, Jung‐Kyu Lee, Nakwon Kwak, Joong Hyun Ahn, Tae Sun Shim, Song Yee Kim, Seungmo Kim, Kyungjong Kim, Kwang-Hyuk Seok, Soyeong Yoon, Young Ran Kim, Jisu Kim, Dahae Yim, Seokyung Hahn, Sang Nae Cho, Jae‐Joon Yim